Fresenius Kabi Limited has published its Cabon Reduction Plan
The UK Government amended the Climate Change Act 2008 in 2019 introducing a target of at least a 100% reduction in the net carbon account (reduction of greenhouse gas emissions compared to 1990 levels) by 2050. This is the Net Zero Target.
Fresenius Kabi Limited (Fresenius Kabi) is part of the Fresenius Kabi global healthcare organisation that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi is a division of the healthcare group Fresenius SE & Co. KGaA. In the UK FHC (Holdings) Limited is the holding company to two subsidiaries: Fresenius Kabi and Calea UK Limited (Calea). These companies are healthcare companies involved in producing pharmaceutical products, controlled drugs, nutritional feed and nursing services. Both companies operate out of two sites in Runcorn; these consist of warehouse space, offices, and an aseptic compounding unit. Fresenius Kabi is a large unquoted company under the Streamlined Energy and Carbon Reporting regulations by virtue of meeting both financial and employee thresholds.
Fresenius Kabi has reported most of its scope 1 and scope 2 emissions for the 2020 period under these regulations. This plan covers all scope 1 and 2 emissions in line with the GHG Protocol Corporate Standard and Action Note PPN 06/21. Work is currently being done to map scope 3 emissions and an interim report will follow.
Commitment to achieving Net Zero
Fresenius Kabi is committed to achieving Net Zero emissions by 2045.
You read the full Carbon Reduction Plan here